Clinical trial
A Phase 3, Randomized, Double-Blind, Fixed-Dose, Parallel Group Comparison of Controlled-Release Hydromorphone HCI vs Placebo in Subjects With Osteoarthritis
NCT00411164 is registered in ClinicalTrials.gov with Alza Corporation, DE, USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Fixed-Dose, Parallel Group Comparison of Controlled-Release Hydromorphone HCI vs Placebo in Subjects With Osteoarthritis
- Lead sponsor
- Alza Corporation, DE, USA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2003
- Completion date
- May 31, 2005
- Enrollment
- 990 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.